help button home button Endocrine Society JCEM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH

This version published online on August 22, 2006
Journal of Clinical Endocrinology & Metabolism, doi:10.1210/jc.2006-0401
A more recent version of this article appeared on November 1, 2006
This Article
Right arrow Author Manuscript (PDF)
Right arrow Supplemental Data
Right arrow All Versions of this Article:
91/11/4335    most recent
Author Manuscript (PDF)
Right arrow Submit a related Letter to the Editor
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Zitzmann, M.
Right arrow Articles by Nieschlag, E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Zitzmann, M.
Right arrow Articles by Nieschlag, E.
Right arrowPubmed/NCBI databases
*Compound via MeSH
*Substance via MeSH
Medline Plus Health Information
*Metabolic Syndrome
*Seniors' Health
Hazardous Substances DB
*TESTOSTERONE

Submitted on February 22, 2006
Accepted on August 10, 2006

Association of specific symptoms and metabolic risks with serum testosterone in older men

Michael Zitzmann, Stephanie Faber, and Eberhard Nieschlag*

Institute of Reproductive Medicine of the University, D-48129 Münster, Germany

* To whom correspondence should be addressed. E-mail: Eberhard.Nieschlag{at}ukmuenster.de.

Context Although attention and concern about health disorders in aging men have been growing, the structure of psychological and somatic complaints of actual patients, not population-based cohorts, has not been elucidated in relation to sex hormone patterns and metabolism.

Objective Investigation of factors influencing complaint structures in aging male patients.

Design Cross-sectional cohort study.

Setting Andrological outpatient department.

Patients 434 consecutive male patients aged 50-86 yr.

Main outcome measures Hypotheses: a) psychosomatic complaints and metabolic factors in aging male patients are related to sex hormone levels in a symptom-specific manner, b) patients form sub-cohorts.

Results A clear-cut threshold for late-onset hypogonadism was not found; rather, prevalence of psychosomatic symptoms and metabolic risk factors accumulated with decreasing androgen levels. For example, androgen-induced prevalence of loss of libido or vigor increased below testosterone concentrations of 15 nmol/L (P < 0.001), while depression and diabetes mellitus type 2 (also in non-obese men) were significantly more present in men with testosterone concentrations <10 nmol/L (P < 0.001). Erectile dysfunction was identified as a composite pathology of metabolic risk factors, smoking and depressivity, while testosterone concentrations contributed to that symptom only <8 nmol/L (P = 0.003). Cluster analysis revealed aging men to present within three independent groups characterized by 1) psychosomatic complaints, 2) metabolic disorders and 3) sexual health problems. These sub-groups of patients exhibit distinct features in terms of androgen levels, age and body mass index.

Conclusions There is no evidence that a uniform structure of testosterone concentrations and complaints exists within the cohort of elderly male patients. Rather, in aging male patients, psychosomatic complaints and metabolic risk relate to testosterone in a symptom-specific manner.




This article has been cited by other articles:


Home page
Physiol. GenomicsHome page
H. E. MacLean, W. S. M. Chiu, C. Ma, J. F. McManus, R. A. Davey, R. Cameron, A. J. Notini, and J. D. Zajac
A floxed allele of the androgen receptor gene causes hyperandrogenization in male mice
Physiol Genomics, March 14, 2008; 33(1): 133 - 137.
[Abstract] [Full Text] [PDF]


Home page
J AndrolHome page
F. Saad, L. J. Gooren, A. Haider, and A. Yassin
A Dose-Response Study of Testosterone on Sexual Dysfunction and Features of the Metabolic Syndrome Using Testosterone Gel and Parenteral Testosterone Undecanoate
J Androl, January 1, 2008; 29(1): 102 - 105.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
A. B. Araujo, G. R. Esche, V. Kupelian, A. B. O'Donnell, T. G. Travison, R. E. Williams, R. V. Clark, and J. B. McKinlay
Prevalence of Symptomatic Androgen Deficiency in Men
J. Clin. Endocrinol. Metab., November 1, 2007; 92(11): 4241 - 4247.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
M. Zitzmann and E. Nieschlag
Androgen Receptor Gene CAG Repeat Length and Body Mass Index Modulate the Safety of Long-Term Intramuscular Testosterone Undecanoate Therapy in Hypogonadal Men
J. Clin. Endocrinol. Metab., October 1, 2007; 92(10): 3844 - 3853.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 2006 by The Endocrine Society